Basilea enters distribution deal for Canada

14 June 2017

Swiss drugmaker Basilea Pharmaceutica (SIX: BSLN) has entered into a distribution and license agreement with Avir Pharma for Basilea's antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole) in Canada.

Under the terms of the agreement, Avir is granted an exclusive license to commercialize isavuconazole and ceftobiprole in the Canadian market. Basilea will receive an undisclosed upfront payment and is eligible to receive milestone payments upon achievement of regulatory and commercial milestones.

Avir plans to apply for a marketing authorization for isavuconazole in Canada. Zevtera is already approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and for the treatment of community-acquired pneumonia (CAP). Avir will be purchasing product from Basilea and be responsible for commercialization in Canada.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK